Collegium Pharmaceutical, Inc. (COLL)
27.35
+0.24
(+0.89%)
USD |
NASDAQ |
Aug 24, 16:00
27.39
+0.04
(+0.14%)
After-Hours: 20:00
Collegium Pharmaceutical Net Income (Quarterly) : -15.05M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.05M |
| March 31, 2026 | 14.50M |
| December 31, 2025 | 16.96M |
| September 30, 2025 | 31.51M |
| June 30, 2025 | 11.98M |
| March 31, 2025 | 2.417M |
| December 31, 2024 | 12.54M |
| September 30, 2024 | 9.335M |
| June 30, 2024 | 19.61M |
| March 31, 2024 | 27.71M |
| December 31, 2023 | 31.94M |
| September 30, 2023 | 20.63M |
| June 30, 2023 | 13.01M |
| March 31, 2023 | -17.43M |
| December 31, 2022 | -7.199M |
| September 30, 2022 | 0.457M |
| June 30, 2022 | -5.191M |
| March 31, 2022 | -13.07M |
| December 31, 2021 | -25.03M |
| September 30, 2021 | 8.046M |
| June 30, 2021 | 72.84M |
| March 31, 2021 | 15.66M |
| December 31, 2020 | 6.958M |
| Date | Value |
|---|---|
| September 30, 2020 | 11.29M |
| June 30, 2020 | 8.058M |
| March 31, 2020 | 0.45M |
| December 31, 2019 | -2.201M |
| September 30, 2019 | -6.109M |
| June 30, 2019 | -4.712M |
| March 31, 2019 | -9.70M |
| December 31, 2018 | 9.086M |
| September 30, 2018 | -16.50M |
| June 30, 2018 | -13.06M |
| March 31, 2018 | -18.65M |
| December 31, 2017 | -17.40M |
| September 30, 2017 | -13.26M |
| June 30, 2017 | -21.12M |
| March 31, 2017 | -23.08M |
| December 31, 2016 | -27.56M |
| September 30, 2016 | -26.44M |
| June 30, 2016 | -24.52M |
| March 31, 2016 | -15.65M |
| December 31, 2015 | -9.525M |
| September 30, 2015 | -9.362M |
| June 30, 2015 | -4.674M |
| March 31, 2015 | -3.694M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Innoviva, Inc. | -83.42M |
| Zevra Therapeutics, Inc. | 8.393M |
| Supernus Pharmaceuticals, Inc. | -58.37M |
| Indivior Pharmaceuticals, Inc. | 122.00M |
| Crinetics Pharmaceuticals, Inc. | -120.86M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 199.88M |
| Total Expenses (Quarterly) | 214.93M |
| EPS Diluted (Quarterly) | -0.4637 |
| Enterprise Value | 1.957B |
| Gross Profit Margin (Quarterly) | 55.18% |
| Profit Margin (Quarterly) | -7.53% |
| Earnings Yield | 4.51% |
| Operating Earnings Yield | 15.64% |
| Normalized Earnings Yield | 5.899 |